The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients

被引:124
|
作者
Flechner, SM [1 ]
Zhou, LM [1 ]
Derweesh, I [1 ]
Mastroianni, B [1 ]
Savas, K [1 ]
Goldfarb, D [1 ]
Modlin, CS [1 ]
Krishnamurthi, V [1 ]
Novick, A [1 ]
机构
[1] Cleveland Clin Fdn, Transplant Ctr, Glickman Urol Inst, Sect Renal Transplantat, Cleveland, OH 44195 USA
关键词
D O I
10.1097/01.TP.0000093502.26208.42
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The aim of this study was to determine whether there has been an increase in the incidence or severity of wound-healing complications that can be attributed to the introduction of newer immunosuppressive drugs. Methods. Consecutive series of adult kidney-only transplant recipients were selected from our Unified Transplant Database backward from September 2002. There were 513 patients divided into groups on the basis of their maintenance immunosuppression given for at least the first 30 days posttransplant. Group I (152) was given sirolimus, mycophenolate mofetil, and prednisone (SRL/XMF/P) between March 2000 and September 2002; group II (168) was given cyclosporine A (CsA)/MMF/P between January 1999 and July 2002; and group III (193) was given azathioprine (AzA)/CsA/P between January 1993 and December 1997. A classification system for wound-healing problems was developed, and each of the three groups was analyzed by univariate and multivariate analysis. Results. From groups III to II to 1, there was a significant increase in mean age (42.4 vs. 49 years), percent of patients diabetic (17% vs. 29%), mean body mass index (BMI) (24.2 vs. 27.1 kg/m(2)), and percent BMI greater than 30 (13.5% vs. 27%). The cumulative percentage of all wound-healing problems between group I (19.7%) vs. group II (16.1%) and group III (15.6%) was not significantly different. The most significant risk factor was a recipient BMI greater than 30 (P=0.0012) and delayed graft function (P=0.0041). Conclusions. During a 10-year period marked by changing recipient demographics, the introduction of MMF and SRL did not result in a significant increase in transplant wound-healing complications. The most significant risk factor associated with transplant wound-healing complications remains body weight, which was the major influence for each of the immunosuppressive drug combinations described.
引用
收藏
页码:1729 / 1734
页数:6
相关论文
共 50 条
  • [21] Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine
    Lobritto, Steven J.
    Rosenthal, Philip
    Bouw, Rene
    Leung, Mimi
    Snell, Paul
    Mamelok, Richard D.
    [J]. LIVER TRANSPLANTATION, 2007, 13 (11) : 1570 - 1575
  • [22] Elective withdrawal of mycophenolate mofetil in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone
    ter Meulen, CG
    Gregoor, PJHS
    Weimar, W
    Hilbrands, LB
    [J]. TRANSPLANT INTERNATIONAL, 2001, 14 (02) : 99 - 102
  • [23] THE MANAGEMENT OF KIDNEY-TRANSPLANT RECIPIENTS TREATED WITH CYCLOSPORINE
    KAHAN, BD
    [J]. TRANSPLANTATION PROCEEDINGS, 1983, 15 (04) : 2641 - 2648
  • [24] Clinical Outcomes of Early Mycophenolate Mofetil Reduction Protocol in Kidney-Transplant Recipients Desensitized with Rituximab
    Kim, S. -M
    Park, S. -K
    Kim, J. -S
    [J]. TRANSPLANTATION, 2012, 94 (10) : 1063 - 1063
  • [25] STEROIDS CAN BE STOPPED IN KIDNEY-TRANSPLANT RECIPIENTS
    STEINMAN, TI
    ZIMMERMAN, CE
    MONACO, AP
    BROWN, RS
    YAGER, HM
    CLIVE, DM
    RANSIL, BJ
    [J]. TRANSPLANTATION PROCEEDINGS, 1981, 13 (01) : 323 - 327
  • [26] Pharmacokinetic monitoring of mycophenolate mofetil in de novo kidney-transplant patients receiving belatacept or cyclosporine A.
    Kamar, Nassim
    Ribes, David
    Lavit, Michel
    Esposito, Laure
    Lavayssiere, Laurence
    Cointault, Olivier
    Saivin, Sylvie
    Durand, Dominique
    Rostaing, Lionel
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 349 - 349
  • [27] Impact of Sirolimus versus Mycophenolate Mofetil on Kidney Function after Calcineurin Inhibitor Dose Reduction in Liver Transplant Recipients
    Chiang, Heng-Yi
    Li, Lung-Chih
    Hsu, Chien-Ning
    Lin, Chih-Che
    Chan, Yi-Chia
    Wang, Chih-Chi
    Chen, Chao-Long
    [J]. PHARMACEUTICALS, 2023, 16 (08)
  • [28] Effects of mycophenolate mofetil and azathioprine on the erythropoietin production in renal transplant recipients
    Montanaro, D
    Gropuzzo, M
    Tulissi, P
    Boscutti, G
    Risaliti, A
    Baccarani, U
    Sainz, M
    Mioni, G
    [J]. TRANSPLANTATION PROCEEDINGS, 2001, 33 (7-8) : 3253 - 3255
  • [29] COMBINATION THERAPY OF CYCLOSPORINE AND AZATHIOPRINE IN LIVING-RELATED KIDNEY-TRANSPLANT RECIPIENTS COMPARED WITH PATIENTS CONVERTED TOTALLY FROM CYCLOSPORINE TO AZATHIOPRINE
    OKA, T
    OMORI, Y
    AIKAWA, I
    YASUMURA, T
    YOSHIMURA, N
    NAKAI, I
    [J]. TRANSPLANTATION PROCEEDINGS, 1988, 20 (03) : 143 - 146
  • [30] Mycophenolate mofetil levels in stable kidney transplant recipients
    Fernandez, A.
    Marcen, R.
    Pascual, J.
    Martins, J.
    Villafruela, J. J.
    Cano, T.
    Sabater, J.
    Puig, C.
    Gil-Casares, B.
    Muriel, A.
    Burgos, J.
    Ortuna, J.
    [J]. TRANSPLANTATION PROCEEDINGS, 2007, 39 (07) : 2182 - 2184